Published in Brain on November 25, 2003
Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron (2009) 3.11
Methamphetamine toxicity and messengers of death. Brain Res Rev (2009) 2.69
The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci (2006) 2.46
Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry (2005) 1.73
Pharmacologic mechanisms of crystal meth. CMAJ (2008) 1.60
Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci (2008) 1.54
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48
Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) (2006) 1.48
Clinical imaging in regenerative medicine. Nat Biotechnol (2014) 1.43
Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J Pharmacol Exp Ther (2009) 1.43
Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage (2008) 1.35
Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav (2010) 1.29
Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry (2008) 1.25
Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS One (2010) 1.22
Altered neurometabolites and motor integration in children exposed to methamphetamine in utero. Neuroimage (2009) 1.18
Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl) (2008) 1.09
Methamphetamine influences on brain and behavior: unsafe at any speed? Trends Neurosci (2012) 0.96
Neurologic manifestations of chronic methamphetamine abuse. Neurol Clin (2011) 0.96
Age-dependent effects of neonatal methamphetamine exposure on spatial learning. Behav Pharmacol (2007) 0.95
Higher diffusion in striatum and lower fractional anisotropy in white matter of methamphetamine users. Psychiatry Res (2009) 0.91
Dopamine transporter trafficking: rapid response on demand. Future Neurol (2010) 0.88
Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat. Psychopharmacology (Berl) (2011) 0.87
Methamphetamine abuse, HIV infection, and neurotoxicity. Int J Physiol Pathophysiol Pharmacol (2009) 0.87
Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin North Am (2013) 0.87
Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology (2007) 0.86
Methamphetamine and Parkinson's disease. Parkinsons Dis (2013) 0.86
Methamphetamine treatment causes delayed decrease in novelty-induced locomotor activity in mice. Neurosci Res (2009) 0.85
Striatal volume increases in active methamphetamine-dependent individuals and correlation with cognitive performance. Brain Sci (2012) 0.84
Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cδ. Behav Brain Res (2012) 0.82
Pharmacotherapy for stimulant-related disorders. Curr Psychiatry Rep (2013) 0.82
Methamphetamine-induced neurotoxicity disrupts naturally occurring phasic dopamine signaling. Eur J Neurosci (2013) 0.82
HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads. Front Microbiol (2015) 0.80
Methamphetamine effects on blood-brain barrier structure and function. Front Neurosci (2015) 0.78
Parkinsonism in patients with a history of amphetamine exposure. Mov Disord (2010) 0.78
Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure. J Biol Chem (2015) 0.78
The Basal Ganglia as a Substrate for the Multiple Actions of Amphetamines. Basal Ganglia (2011) 0.78
Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence. Neuropsychopharmacology (2015) 0.77
Functional and structural brain changes associated with methamphetamine abuse. Brain Sci (2012) 0.77
Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence. Eur J Neurosci (2016) 0.76
Fragment C Domain of Tetanus Toxin Mitigates Methamphetamine Neurotoxicity and Its Motor Consequences in Mice. Int J Neuropsychopharmacol (2016) 0.75
Current concepts in the diagnosis and management of Parkinson's disease. CMAJ (2003) 1.83
Dopamine modulates the plasticity of mechanosensory responses in Caenorhabditis elegans. EMBO J (2004) 1.79
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain (2009) 1.44
Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms. Mov Disord (2012) 1.44
Mitochondria in Alzheimer's disease. Int Rev Neurobiol (2002) 1.40
Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem (2003) 1.28
Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend (2011) 1.25
Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord (2010) 1.20
The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction (2013) 1.15
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci (2008) 1.12
Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2013) 1.12
Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry (2012) 1.09
Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl) (2008) 1.09
Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J Pharmacol Exp Ther (2006) 1.07
Brain vesicular acetylcholine transporter in human users of drugs of abuse. Synapse (2004) 1.05
Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology (2008) 1.01
Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry (2011) 0.98
Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse (2008) 0.96
Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain (2009) 0.96
Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab (2012) 0.93
Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord (2008) 0.93
The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiol Aging (2011) 0.93
Brain antioxidant systems in human methamphetamine users. J Neurochem (2004) 0.92
All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. Drug Alcohol Depend (2012) 0.90
Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline. Arch Neurol (2006) 0.87
[¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. Mov Disord (2015) 0.86
Does hyperthyroidism increase risk of death due to the ingestion of ecstasy? J Forensic Sci (2007) 0.86
Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology (2007) 0.86
Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens. J Neurochem (2007) 0.85
Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia. Ann Neurol (2002) 0.85
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Mov Disord (2004) 0.84
Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans. Synapse (2010) 0.83
Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord (2003) 0.83
Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2011) 0.83
Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci (2004) 0.82
Identification of a noradrenaline-rich subdivision of the human nucleus accumbens. J Neurochem (2005) 0.81
Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine. Drug Alcohol Depend (2002) 0.81
Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann Neurol (2002) 0.81
Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (2004) 0.81
Dextromethorphan abuse leading to assault, suicide, or homicide. J Forensic Sci (2012) 0.80
Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain. Neurobiol Dis (2010) 0.80
Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am J Psychiatry (2003) 0.80
Serum calcium-independent phospholipase A2 activity in bipolar affective disorder. Bipolar Disord (2006) 0.79
Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study. J Cereb Blood Flow Metab (2011) 0.78
What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease? Mov Disord (2003) 0.77
Histologic evidence of repetitive blunt force abdominal trauma in four pediatric fatalities. J Forensic Sci (2008) 0.77
TRPC3 protein is expressed across the lifespan in human prefrontal cortex and cerebellum. Brain Res (2009) 0.77
Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency. Ann Neurol (2004) 0.76
Effects of MDMA (ecstasy) use and abstention on serotonin neurons. Lancet (2002) 0.75
Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur J Pharmacol (2002) 0.75
Takotsubo cardiomyopathy associated with lithium intoxication in bipolar disorder: a case report. J Clin Psychopharmacol (2014) 0.75
Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications. Eur J Neurosci (2017) 0.75
Altered CTX-catalyzed and endogenous [32P]ADP-ribosylation of stimulatory G protein alphas isoforms in postmortem bipolar affective disorder temporal cortex. J Neurosci Res (2003) 0.75
Incidence of autopsy findings in unexpected deaths of children and adolescents. Pediatr Dev Pathol (2002) 0.75
The value and availability of forensic anthropological consultation in medicolegal death investigations. Forensic Sci Med Pathol (2015) 0.75
The final consult: improving service to families after the death of a patient. Iowa Med (2010) 0.75